Welcome to LookChem.com Sign In|Join Free
  • or
13-CIS-RETINOL, also known as 13-cis-Retinol, is one of the active metabolites of Vitamin A (R252000). It is a yellow, low melting solid with significant biological activities and potential applications in various industries.

2052-63-3

Post Buying Request

2052-63-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2052-63-3 Usage

Uses

Used in Pharmaceutical Industry:
13-CIS-RETINOL is used as a therapeutic agent for its role in treating various skin conditions and promoting skin health. It is particularly effective in managing acne, psoriasis, and other skin disorders due to its ability to regulate cell growth and differentiation.
Used in Cosmetic Industry:
In the cosmetic industry, 13-CIS-RETINOL is used as an active ingredient in anti-aging and skin rejuvenation products. It helps to reduce the appearance of fine lines, wrinkles, and age spots by stimulating collagen production and promoting skin cell turnover.
Used in Nutritional Supplements:
13-CIS-RETINOL is also used as an additive in nutritional supplements to support overall health and well-being. As a metabolite of Vitamin A, it plays a crucial role in maintaining healthy vision, immune function, and reproductive health.
Used in Research and Development:
Due to its unique chemical properties and biological activities, 13-CIS-RETINOL is utilized in research and development for the discovery of new drugs and therapies. It serves as a valuable tool in studying the mechanisms of cell growth, differentiation, and apoptosis, which can lead to the development of novel treatments for various diseases and conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 2052-63-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,0,5 and 2 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 2052-63:
(6*2)+(5*0)+(4*5)+(3*2)+(2*6)+(1*3)=53
53 % 10 = 3
So 2052-63-3 is a valid CAS Registry Number.
InChI:InChI=1/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13-

2052-63-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 13-cis-retinol

1.2 Other means of identification

Product number -
Other names 13-cis-Retinol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:2052-63-3 SDS

2052-63-3Synthetic route

1-acetoxy-3,7-dimethyl-8-(tetrahydropyran-2-yl)oxy-9-phenylsulfonyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2(E),6(E)-nonadiene
103905-07-3

1-acetoxy-3,7-dimethyl-8-(tetrahydropyran-2-yl)oxy-9-phenylsulfonyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2(E),6(E)-nonadiene

A

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

C

11-cis-retinol
22737-96-8

11-cis-retinol

D

RETINOL
68-26-8

RETINOL

Conditions
ConditionsYield
With potassium methanolate In cyclohexane at 38℃; for 2h;A n/a
B n/a
C n/a
D 77%
With potassium methanolate In cyclohexane at 38℃; for 2h; Title compound not separated from byproducts;
9-(2',6',6'-trimethylcyclohex-1'-enyl)-8-acetoxy-3,7-dimethyl-9-(p-tolylsulfonyl)nona-2Z,4E,6E-trien-1-ol
181053-77-0

9-(2',6',6'-trimethylcyclohex-1'-enyl)-8-acetoxy-3,7-dimethyl-9-(p-tolylsulfonyl)nona-2Z,4E,6E-trien-1-ol

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
With methanol; potassium dihydrogenphosphate; sodium amalgam In diethyl ether for 0.5h; Ambient temperature;63%
With potassium dihydrogenphosphate; sodium amalgam In diethyl ether; ethanol at 20℃; for 0.5h;63%
(2Z,4E,6E,8E)-methyl 3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoate
16760-45-5

(2Z,4E,6E,8E)-methyl 3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoate

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
With lithium aluminium tetrahydride; diethyl ether at -50℃;
triethylsilyl ether of 13-cis-retinol
118304-60-2

triethylsilyl ether of 13-cis-retinol

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
With pyridine hydrogenfluoride; sodium fluoride Ambient temperature; Yield given;
With pyridine hydrogenfluoride; sodium fluoride In tetrahydrofuran; acetonitrile for 5h; Ambient temperature;
Acetic acid (2Z,6E)-9-benzenesulfonyl-3,7-dimethyl-8-(tetrahydro-pyran-2-yloxy)-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,6-dienyl ester
103905-07-3, 105615-50-7

Acetic acid (2Z,6E)-9-benzenesulfonyl-3,7-dimethyl-8-(tetrahydro-pyran-2-yloxy)-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,6-dienyl ester

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
With potassium methanolate In cyclohexane at 38℃; for 2h;
Acetic acid (2Z,6E)-9-benzenesulfonyl-3,7-dimethyl-8-(tetrahydro-pyran-2-yloxy)-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,6-dienyl ester
103905-07-3, 105615-50-7

Acetic acid (2Z,6E)-9-benzenesulfonyl-3,7-dimethyl-8-(tetrahydro-pyran-2-yloxy)-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,6-dienyl ester

A

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

B

11,13-Di-cis-vitamin A
17706-49-9

11,13-Di-cis-vitamin A

C

(9Z,13Z)-retinol
29444-25-5

(9Z,13Z)-retinol

D

RETINOL
68-26-8

RETINOL

Conditions
ConditionsYield
With potassium methanolate In cyclohexane at 38℃; for 2h; Yield given. Title compound not separated from byproducts;
With potassium methanolate In cyclohexane at 38℃; for 2h; Title compound not separated from byproducts;
O-all-trans-retinol

O-all-trans-retinol

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
With iodine; benzene Einwirkung von Tageslicht;
ethyl (2E,4E,6Z)-8-hydroxy-2,6-dimethylocta-2,4,6-trienoate
181053-78-1

ethyl (2E,4E,6Z)-8-hydroxy-2,6-dimethylocta-2,4,6-trienoate

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1.1: 98 percent / imidazole / dimethylformamide / 1 h / 20 °C
2.1: 96 percent / LiAlH4; AlCl3 / diethyl ether / 3 h / 0 °C
3.1: 100 percent / MnO2 / hexane; CHCl3 / 12 h / 20 °C
4.1: n-BuLi / tetrahydrofuran; hexane / 1 h / -78 °C
4.2: tetrahydrofuran; hexane / 3 h / -78 °C
5.1: 118.2 mg / tetrahydrofuran; hexane / -78 - 20 °C
6.1: 99 percent / TBAF / tetrahydrofuran / 0.5 h / 20 °C
7.1: 63 percent / KH2PO4; Na/Hg / ethanol; diethyl ether / 0.5 h / 20 °C
View Scheme
Multi-step reaction with 6 steps
1: 98 percent
2: 96 percent / AlCl3, LiAlH4
3: 100 percent / MnO2
4: 1.) nBuLi
5: n-Bu4NF
6: 63 percent / Na/Hg, KH2PO4, MeOH / diethyl ether / 0.5 h / Ambient temperature
View Scheme
ethyl (2E,4E,6Z)-8-tert-butyldimethylsiloxy-2,6-dimethylocta-2,4,6-trienoate
181053-73-6

ethyl (2E,4E,6Z)-8-tert-butyldimethylsiloxy-2,6-dimethylocta-2,4,6-trienoate

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1.1: TBAF / tetrahydrofuran / 0.5 h / 20 °C
2.1: 98 percent / imidazole / dimethylformamide / 1 h / 20 °C
3.1: 96 percent / LiAlH4; AlCl3 / diethyl ether / 3 h / 0 °C
4.1: 100 percent / MnO2 / hexane; CHCl3 / 12 h / 20 °C
5.1: n-BuLi / tetrahydrofuran; hexane / 1 h / -78 °C
5.2: tetrahydrofuran; hexane / 3 h / -78 °C
6.1: 118.2 mg / tetrahydrofuran; hexane / -78 - 20 °C
7.1: 99 percent / TBAF / tetrahydrofuran / 0.5 h / 20 °C
8.1: 63 percent / KH2PO4; Na/Hg / ethanol; diethyl ether / 0.5 h / 20 °C
View Scheme
(3E,6Z)-8-(tert-Butyl-dimethyl-silanyloxy)-2-(N,N-dimethyl-aminooxy)-2,6-dimethyl-octa-3,6-dienoic acid ethyl ester
181053-74-7

(3E,6Z)-8-(tert-Butyl-dimethyl-silanyloxy)-2-(N,N-dimethyl-aminooxy)-2,6-dimethyl-octa-3,6-dienoic acid ethyl ester

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 9 steps
1.1: methanol / 72 h / 20 °C
2.1: TBAF / tetrahydrofuran / 0.5 h / 20 °C
3.1: 98 percent / imidazole / dimethylformamide / 1 h / 20 °C
4.1: 96 percent / LiAlH4; AlCl3 / diethyl ether / 3 h / 0 °C
5.1: 100 percent / MnO2 / hexane; CHCl3 / 12 h / 20 °C
6.1: n-BuLi / tetrahydrofuran; hexane / 1 h / -78 °C
6.2: tetrahydrofuran; hexane / 3 h / -78 °C
7.1: 118.2 mg / tetrahydrofuran; hexane / -78 - 20 °C
8.1: 99 percent / TBAF / tetrahydrofuran / 0.5 h / 20 °C
9.1: 63 percent / KH2PO4; Na/Hg / ethanol; diethyl ether / 0.5 h / 20 °C
View Scheme
(2E,4E,6Z)-8-tert-butyldiphenylsiloxy-2,6-dimethylocta-2,4,6-trien-1-ol
181053-80-5

(2E,4E,6Z)-8-tert-butyldiphenylsiloxy-2,6-dimethylocta-2,4,6-trien-1-ol

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: 100 percent / MnO2 / hexane; CHCl3 / 12 h / 20 °C
2.1: n-BuLi / tetrahydrofuran; hexane / 1 h / -78 °C
2.2: tetrahydrofuran; hexane / 3 h / -78 °C
3.1: 118.2 mg / tetrahydrofuran; hexane / -78 - 20 °C
4.1: 99 percent / TBAF / tetrahydrofuran / 0.5 h / 20 °C
5.1: 63 percent / KH2PO4; Na/Hg / ethanol; diethyl ether / 0.5 h / 20 °C
View Scheme
Multi-step reaction with 4 steps
1: 100 percent / MnO2
2: 1.) nBuLi
3: n-Bu4NF
4: 63 percent / Na/Hg, KH2PO4, MeOH / diethyl ether / 0.5 h / Ambient temperature
View Scheme
(2E,4E,6Z)-8-tert-butyldiphenylsiloxy-2,6-dimethylocta-2,4,6-trienal
181053-76-9

(2E,4E,6Z)-8-tert-butyldiphenylsiloxy-2,6-dimethylocta-2,4,6-trienal

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: n-BuLi / tetrahydrofuran; hexane / 1 h / -78 °C
1.2: tetrahydrofuran; hexane / 3 h / -78 °C
2.1: 118.2 mg / tetrahydrofuran; hexane / -78 - 20 °C
3.1: 99 percent / TBAF / tetrahydrofuran / 0.5 h / 20 °C
4.1: 63 percent / KH2PO4; Na/Hg / ethanol; diethyl ether / 0.5 h / 20 °C
View Scheme
Multi-step reaction with 3 steps
1: 1.) nBuLi
2: n-Bu4NF
3: 63 percent / Na/Hg, KH2PO4, MeOH / diethyl ether / 0.5 h / Ambient temperature
View Scheme
ethyl (2E,4E,6Z)-8-tert-butyldiphenylsiloxy-2,6-dimethylocta-2,4,6-trienoate
181053-79-2

ethyl (2E,4E,6Z)-8-tert-butyldiphenylsiloxy-2,6-dimethylocta-2,4,6-trienoate

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1.1: 96 percent / LiAlH4; AlCl3 / diethyl ether / 3 h / 0 °C
2.1: 100 percent / MnO2 / hexane; CHCl3 / 12 h / 20 °C
3.1: n-BuLi / tetrahydrofuran; hexane / 1 h / -78 °C
3.2: tetrahydrofuran; hexane / 3 h / -78 °C
4.1: 118.2 mg / tetrahydrofuran; hexane / -78 - 20 °C
5.1: 99 percent / TBAF / tetrahydrofuran / 0.5 h / 20 °C
6.1: 63 percent / KH2PO4; Na/Hg / ethanol; diethyl ether / 0.5 h / 20 °C
View Scheme
Multi-step reaction with 5 steps
1: 96 percent / AlCl3, LiAlH4
2: 100 percent / MnO2
3: 1.) nBuLi
4: n-Bu4NF
5: 63 percent / Na/Hg, KH2PO4, MeOH / diethyl ether / 0.5 h / Ambient temperature
View Scheme
9-(2',6',6'-trimethylcyclohex-1'-enyl)-8-acetoxy-1-tert-butyldiphenylsiloxy-3,7-dimethyl-9-(p-tolylsulfonyl)nona-2Z,4E,6E-triene
463302-50-3

9-(2',6',6'-trimethylcyclohex-1'-enyl)-8-acetoxy-1-tert-butyldiphenylsiloxy-3,7-dimethyl-9-(p-tolylsulfonyl)nona-2Z,4E,6E-triene

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 99 percent / TBAF / tetrahydrofuran / 0.5 h / 20 °C
2: 63 percent / KH2PO4; Na/Hg / ethanol; diethyl ether / 0.5 h / 20 °C
View Scheme
Multi-step reaction with 2 steps
1: n-Bu4NF
2: 63 percent / Na/Hg, KH2PO4, MeOH / diethyl ether / 0.5 h / Ambient temperature
View Scheme
(3E,5E,7Z)-9-(tert-Butyl-diphenyl-silanyloxy)-3,7-dimethyl-1-(toluene-4-sulfonyl)-1-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-3,5,7-trien-2-ol

(3E,5E,7Z)-9-(tert-Butyl-diphenyl-silanyloxy)-3,7-dimethyl-1-(toluene-4-sulfonyl)-1-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-3,5,7-trien-2-ol

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 118.2 mg / tetrahydrofuran; hexane / -78 - 20 °C
2: 99 percent / TBAF / tetrahydrofuran / 0.5 h / 20 °C
3: 63 percent / KH2PO4; Na/Hg / ethanol; diethyl ether / 0.5 h / 20 °C
View Scheme
β-cyclogeranyl p-tolyl sulfone

β-cyclogeranyl p-tolyl sulfone

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 1.) nBuLi
2: n-Bu4NF
3: 63 percent / Na/Hg, KH2PO4, MeOH / diethyl ether / 0.5 h / Ambient temperature
View Scheme
C20H39NO4Si
181053-72-5

C20H39NO4Si

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: 100 percent / n-Bu4NF
2: 98 percent
3: 96 percent / AlCl3, LiAlH4
4: 100 percent / MnO2
5: 1.) nBuLi
6: n-Bu4NF
7: 63 percent / Na/Hg, KH2PO4, MeOH / diethyl ether / 0.5 h / Ambient temperature
View Scheme
[(2E)-3-ethoxycarbonylbut-2-enyl][1-isopropenyl-2-(tert-butyldimethylsiloxy)ethyl]dimethylammonium bromide

[(2E)-3-ethoxycarbonylbut-2-enyl][1-isopropenyl-2-(tert-butyldimethylsiloxy)ethyl]dimethylammonium bromide

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 9 steps
1: KOEt / ethanol / 5 h / -70 °C
2: peracetic acid, Na2CO3 / CH2Cl2 / -60 °C
3: 100 percent / n-Bu4NF
4: 98 percent
5: 96 percent / AlCl3, LiAlH4
6: 100 percent / MnO2
7: 1.) nBuLi
8: n-Bu4NF
9: 63 percent / Na/Hg, KH2PO4, MeOH / diethyl ether / 0.5 h / Ambient temperature
View Scheme
(2E,6Z)-8-(tert-Butyl-dimethyl-silanyloxy)-4-dimethylamino-2,6-dimethyl-octa-2,6-dienoic acid ethyl ester
181053-71-4

(2E,6Z)-8-(tert-Butyl-dimethyl-silanyloxy)-4-dimethylamino-2,6-dimethyl-octa-2,6-dienoic acid ethyl ester

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1: peracetic acid, Na2CO3 / CH2Cl2 / -60 °C
2: 100 percent / n-Bu4NF
3: 98 percent
4: 96 percent / AlCl3, LiAlH4
5: 100 percent / MnO2
6: 1.) nBuLi
7: n-Bu4NF
8: 63 percent / Na/Hg, KH2PO4, MeOH / diethyl ether / 0.5 h / Ambient temperature
View Scheme
neryl acetate
141-12-8

neryl acetate

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: SeO2, salicylic acid, tert-butyl hydroperoxide / CH2Cl2 / 27 h / Ambient temperature
2: PDC / CH2Cl2 / 10 h / Ambient temperature
3: 1.) n-BuLi / 1.) THF, -78 deg C, 2 h, 2.) THF, -78 deg C, 3 h
4: p-toluenesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
5: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
Multi-step reaction with 4 steps
1: SeO2, salicylic acid, tert-butyl hydroperoxide / CH2Cl2 / 27 h / Ambient temperature
2: 1.) n-BuLi / 1.) THF, -78 deg C, 2 h, 2.) THF, -78 deg C, 3 h
3: p-toluenesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
4: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
3,7-dimethyl-2E,6-octadien-1-yl acetate
105-87-3

3,7-dimethyl-2E,6-octadien-1-yl acetate

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: SeO2, salicylic acid, tert-butyl hydroperoxide / CH2Cl2 / 27 h / Ambient temperature
2: PDC / CH2Cl2 / 10 h / Ambient temperature
3: 1.) n-BuLi / 1.) THF, -78 deg C, 2 h, 2.) THF, -78 deg C, 3 h
4: 99 percent / p-toluenesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
5: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
Multi-step reaction with 4 steps
1: SeO2, salicylic acid, tert-butyl hydroperoxide / CH2Cl2 / 27 h / Ambient temperature
2: 1.) n-BuLi / 1.) THF, -78 deg C, 2 h, 2.) THF, -78 deg C, 3 h
3: 99 percent / p-toluenesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
4: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
8-hydroxygeranyl acetate
37905-03-6

8-hydroxygeranyl acetate

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: PDC / CH2Cl2 / 10 h / Ambient temperature
2: 1.) n-BuLi / 1.) THF, -78 deg C, 2 h, 2.) THF, -78 deg C, 3 h
3: 99 percent / p-toluenesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
4: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
(2E,6E)-3,7-dimethyl-8-oxoocta-2,6-dien-1-yl acetate
37905-02-5

(2E,6E)-3,7-dimethyl-8-oxoocta-2,6-dien-1-yl acetate

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 1.) n-BuLi / 1.) THF, -78 deg C, 2 h, 2.) THF, -78 deg C, 3 h
2: 99 percent / p-toluenesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
3: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
(2'Z,6'E)-Essigsaeure-(8'-hydroxy-3',7'-dimethyl-2',6'-octadien-1'-yl)ester
70238-37-8

(2'Z,6'E)-Essigsaeure-(8'-hydroxy-3',7'-dimethyl-2',6'-octadien-1'-yl)ester

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: PDC / CH2Cl2 / 10 h / Ambient temperature
2: 1.) n-BuLi / 1.) THF, -78 deg C, 2 h, 2.) THF, -78 deg C, 3 h
3: p-toluenesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
4: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
{[(2,6,6-trimethyl-1-cyclohexen-1-yl)methyl]sulfonyl}benzene
56691-74-8

{[(2,6,6-trimethyl-1-cyclohexen-1-yl)methyl]sulfonyl}benzene

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 1.) n-BuLi / 1.) THF, -78 deg C, 2 h, 2.) THF, -78 deg C, 3 h
2: 99 percent / p-toluenesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
3: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
Multi-step reaction with 3 steps
1: 1.) n-BuLi / 1.) THF, -78 deg C, 2 h, 2.) THF, -78 deg C, 3 h
2: p-toluenesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
3: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
Multi-step reaction with 3 steps
1: n-BuLi / tetrahydrofuran / 5 h / -78 °C
2: p-toluenesulfonic acid / CH2Cl2
3: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
(2Z,6E)-3,7-dimethyl-8-oxoocta-2,6-dien-1-yl acetate
94853-00-6

(2Z,6E)-3,7-dimethyl-8-oxoocta-2,6-dien-1-yl acetate

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 1.) n-BuLi / 1.) THF, -78 deg C, 2 h, 2.) THF, -78 deg C, 3 h
2: p-toluenesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
3: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
Multi-step reaction with 3 steps
1: n-BuLi / tetrahydrofuran / 5 h / -78 °C
2: p-toluenesulfonic acid / CH2Cl2
3: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
Acetic acid (2Z,6E)-9-benzenesulfonyl-8-hydroxy-3,7-dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,6-dienyl ester
105615-49-4

Acetic acid (2Z,6E)-9-benzenesulfonyl-8-hydroxy-3,7-dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,6-dienyl ester

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: p-toluenesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
2: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
Multi-step reaction with 2 steps
1: p-toluenesulfonic acid / CH2Cl2
2: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
1-acetoxy-8-hydroxy-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-9-(phenylsulfonyl)-2(E),6(E)-nonadiene
103905-01-7

1-acetoxy-8-hydroxy-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-9-(phenylsulfonyl)-2(E),6(E)-nonadiene

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 99 percent / p-toluenesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
2: MeOK / cyclohexane / 2 h / 38 °C
View Scheme
5-hydroxy-4-methyl-5H-furan-2-one
40834-42-2

5-hydroxy-4-methyl-5H-furan-2-one

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: 1.) NaH / 1.) HMPA, 0 deg C, 1 h, 2.) 20 min
2: 1.) ethylmagnesium bromide / 1.) THF, room temperature, 1 h, 2.) 15 min
3: 75 percent / DIBAH / tetrahydrofuran; toluene / 0.5 h / -78 °C
4: 90 percent / H2 / Lindlar catalyst / methanol / 24 h
5: 80 percent / imidazole / dimethylformamide / 18 h / Ambient temperature
6: 90 percent / LiAlH4, TiCl3 / tetrahydrofuran / 0.5 h / Ambient temperature
7: sodium fluoride, pyridinium fluoride / tetrahydrofuran; acetonitrile / 5 h / Ambient temperature
View Scheme
Multi-step reaction with 7 steps
1: 85 percent / NaH / hexamethylphosphoric acid triamide
2: 90 percent / EtMgBr
3: 75 percent / DIBAL
4: 80 percent
5: 90 percent / H2 / Lindlar catalist
6: 90 percent / LiAlH4,TiCl3 / tetrahydrofuran / 0.5 h / Ambient temperature
7: NaF, pyridiniumfluoride / Ambient temperature
View Scheme
pyridine
110-86-1

pyridine

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

acetyl chloride
75-36-5

acetyl chloride

(7E,9E,11E,13Z)-retinyl acetate
34356-31-5

(7E,9E,11E,13Z)-retinyl acetate

Conditions
ConditionsYield
With 1,2-dichloro-ethane
pyridine
110-86-1

pyridine

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

n-hexadecanoyl chloride
112-67-4

n-hexadecanoyl chloride

9-Palmitoyloxy-3.7-dimethyl-1t-(2.2.6-trimethyl-cyclohexen-(6)-yl)-nonatetraen-(1.3t.5t.7c)
26771-20-0

9-Palmitoyloxy-3.7-dimethyl-1t-(2.2.6-trimethyl-cyclohexen-(6)-yl)-nonatetraen-(1.3t.5t.7c)

Conditions
ConditionsYield
With 1,2-dichloro-ethane
2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

13-cis-vitamin A aldehyde
472-86-6

13-cis-vitamin A aldehyde

Conditions
ConditionsYield
With manganese(IV) oxide; Petroleum ether unter Lichtausschluss;
With manganese(IV) oxide
With manganese(IV) oxide In tetrachloromethane for 0.5h;
4-phenylazobenzoyl chloride
104-24-5

4-phenylazobenzoyl chloride

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

9-(4-Phenylazo-benzoyloxy)-3.7-dimethyl-1t-(2.2.6-trimethyl-cyclohexen-(6)-yl)-nonatetraen-(1.3t.5t.7c)
50696-24-7, 50837-87-1, 105616-34-0

9-(4-Phenylazo-benzoyloxy)-3.7-dimethyl-1t-(2.2.6-trimethyl-cyclohexen-(6)-yl)-nonatetraen-(1.3t.5t.7c)

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

anthraquinone-2-carbonyl chloride
6470-87-7

anthraquinone-2-carbonyl chloride

O-(9.10-dioxo-9.10-dihydro-anthracenecarbonyl-(2))-[7t.9t.11t.13c]retinol
107892-29-5

O-(9.10-dioxo-9.10-dihydro-anthracenecarbonyl-(2))-[7t.9t.11t.13c]retinol

Conditions
ConditionsYield
With pyridine; dichloromethane
Conditions
ConditionsYield
With triethylamine In hexane Yield given;
2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

acetic anhydride
108-24-7

acetic anhydride

A

9cis,13cis-retinyl acetate
29444-27-7

9cis,13cis-retinyl acetate

B

(7E,9E,11E,13Z)-retinyl acetate
34356-31-5

(7E,9E,11E,13Z)-retinyl acetate

C

11,13-di-cis-Vitamin-A-acetat
63568-38-7

11,13-di-cis-Vitamin-A-acetat

Conditions
ConditionsYield
With triethylamine In hexane Yield given;
2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

propargyl bromide
106-96-7

propargyl bromide

2-((1E,3E,5E,7Z)-3,7-Dimethyl-9-prop-2-ynyloxy-nona-1,3,5,7-tetraenyl)-1,3,3-trimethyl-cyclohexene
173010-18-9

2-((1E,3E,5E,7Z)-3,7-Dimethyl-9-prop-2-ynyloxy-nona-1,3,5,7-tetraenyl)-1,3,3-trimethyl-cyclohexene

Conditions
ConditionsYield
With n-butyllithium 1.) benzene, hexane, 20 deg C, 5 min, 2.) benzene, DMF, hexane, RT, 4 h; Yield given. Multistep reaction;
hydrogenchloride
7647-01-0

hydrogenchloride

2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

anhydrovitamin-A1

anhydrovitamin-A1

Conditions
ConditionsYield
Kinetics; Dehydratisierung;
2-cis-Vitamin-A
2052-63-3

2-cis-Vitamin-A

iodine
7553-56-2

iodine

benzene
71-43-2

benzene

O--derivative of all-trans-retinol

O--derivative of all-trans-retinol

Conditions
ConditionsYield
Gleichgewichtsgemisch mit dem O--Derivat unter der Einwirkung von Tageslicht;

2052-63-3Relevant academic research and scientific papers

Catalytic synthesis of 9-cis-retinoids: Mechanistic insights

Kahremany, Shirin,Kubas, Adam,Tochtrop, Gregory P.,Palczewski, Krzysztof

supporting information, p. 10581 - 10595 (2019/07/22)

The regioselective Z-isomerization of thermodynamically stable all-trans retinoids remains challenging, and ultimately limits the availability of much needed therapeutics for the treatment of human diseases. We present here a novel, straightforward approach for the catalytic Z-isomerization of retinoids using conventional heat treatment or microwave irradiation. A screen of 20 transition metal-based catalysts identified an optimal approach for the regioselective production of Z-retinoids. The most effective catalytic system was comprised of a palladium complex with labile ligands. Several mechanistic studies, including isotopic H/D exchange and state-of-the-art quantum chemical calculations using coupled cluster methods indicate that the isomerization is initiated by catalyst dimerization followed by the formation of a cyclic, six-membered chloropalladate catalyst-substrate adduct, which eventually opens to produce the desired Z-isomer. The synthetic development described here, combined with thorough mechanistic analysis of the underlying chemistry, highlights the use of readily available transition metal-based catalysts in straightforward formats for gram-scale drug synthesis.

Z -isomerization of retinoids through combination of monochromatic photoisomerization and metal catalysis

Kahremany, Shirin,Sander, Christopher Lane,Tochtrop, Gregory P.,Kubas, Adam,Palczewski, Krzysztof

supporting information, p. 8125 - 8139 (2019/09/19)

Catalytic Z-isomerization of retinoids to their thermodynamically less stable Z-isomer remains a challenge. In this report, we present a photochemical approach for the catalytic Z-isomerization of retinoids using monochromatic wavelength UV irradiation treatment. We have developed a straightforward approach for the synthesis of Z-retinoids in high yield, overcoming common obstacles normally associated with their synthesis. Calculations based on density functional theory (DFT) have allowed us to correlate the experimentally observed Z-isomer distribution of retinoids with the energies of chemically important intermediates, which include ground- and excited-state potential energy surfaces. We also demonstrate the application of the current method by synthesizing gram-scale quantities of 9-cis-retinyl acetate 9Z-a. Operational simplicity and gram-scale ability make this chemistry a very practical solution to the problem of Z-isomer retinoid synthesis.

METHOD FOR SYNTHESIS OF 9-CIS-BETA-CAROTENE AND FORMULATIONS THEREOF

-

, (2017/12/29)

The present invention relates to a method for total chemical synthesis of 9-cis-β-carotene (9CBC), and further provides stable formulations thereof.

Substrate specificity and subcellular localization of the aldehyde-Alcohol redox-Coupling reaction in carp cones

Sato, Shinya,Fukagawa, Takashi,Tachibanaki, Shuji,Yamano, Yumiko,Wada, Akimori,Kawamura, Satoru

, p. 36589 - 36597 (2014/01/17)

Our previous study suggested the presence of a novel conespecific redox reaction that generates 11-cis-retinal from 11-cisretinol in the carp retina. This reaction is unique in that 1) both 11-cis-retinol and all-trans-retinal were required to produce 11-cis-retinal; 2) together with 11-cis-retinal, all-trans-retinol was produced at a 1:1 ratio; and 3) the addition of enzyme cofactors such as NADP(H) was not necessary. This reaction is probably part of the reactions in a cone-specific retinoid cycle required for cone visual pigment regeneration with the use of 11-cis-retinol supplied from Mueller cells. In this study, using purified carp cone membrane preparations, we first confirmed that the reaction is a redox-coupling reaction between retinals and retinols. We further examined the substrate specificity, reaction mechanism, and subcellular localization of this reaction. Oxidation was specific for 11-cis-retinol and 9-cis-retinol. In contrast, reduction showed low specificity: many aldehydes, including all-trans-, 9-cis-, 11-cis-, and 13-cis-retinals and even benzaldehyde, supported the reaction. On the basis of kinetic studies of this reaction (aldehyde-alcohol redox-coupling reaction), we found that formation of a ternary complex of a retinol, an aldehyde, and a postulated enzyme seemed to be necessary, which suggested the presence of both the retinol- and aldehydebinding sites in this enzyme. A subcellular fractionation study showed that the activity is present almost exclusively in the cone inner segment. These results suggest the presence of an effective production mechanism of 11-cis-retinal in the cone inner segment to regenerate visual pigment.

Laser flash photolysis study on the retinol radical cation in polar solvents

El-Agamey, Ali,Fukuzumi, Shunichi

scheme or table, p. 6437 - 6446 (2011/10/10)

Laser flash photolysis (LFP) of retinol in argon-saturated methanol gives rise to a transient at 580 nm (transient A). Formation of transient A is accompanied by a transient growth at 370 nm. The rate of this growth is retinol concentration-dependent. The transient growth at 370 nm was removed in the presence of N2O, which is known to scavenge solvated electrons. These results can be interpreted by formation of retinol+ (λmax = 580 nm) and solvated electrons following LFP of retinol. Subsequently, the solvated electrons are rapidly scavenged by retinol to form retinol- (λmax = 370 nm in methanol). On the other hand, transient A is not ascribed to the retinyl cation, as was previously proposed, because the retinyl cation, generated from LFP of retinyl acetate, and transient A show different reactivities towards halide ions (e.g. kBr = 1.7 × 109 and 1.51 × 1010 M-1 s-1 respectively, in acetonitrile). After demonstrating the identity of transient A as retinol+, its reactions with carotenoids were examined in air-saturated polar solvents. In the presence of carotenoids, an enhancement in the decay of retinol+ was observed and was accompanied by formation of the corresponding carotenoid radical cations via electron transfer from carotenoids to retinol+. Furthermore, the reactivity of retinol+ towards pyridine derivatives was investigated in air-saturated polar solvents. It was found that the decay of retinol + was accelerated with concomitant formation, with the same rate, of a transient at 370 nm. Similar observations were obtained with increasing pH of air-saturated aqueous 2% Triton X-100 of retinol+. The 370 nm (or 380 nm in the case of Triton X-100) transient is attributed to the base adducts or deprotonated neutral radicals. On the basis of these results, the reactivities of the retinyl cation and retinol+ are compared and the consequences of retinol+ formation within biological environments are discussed.

All-Trans-Retinol: All-Trans-13,14-Dihydroretinol Saturase and Methods of Its Use

-

Page/Page column 2; 23; Sheet 6/24, (2008/12/08)

Compositions of all-trans-retinol: all-trans-13,14-dihydroretinal saturase and methods of use thereof are provided.

Accurate measurements of 13C-13C J-couplings in the rhodopsin chromophore by double-quantum solid-state NMR spectroscopy

Lai, Wai Cheu,McLean, Neville,Gansmueller, Axel,Verhoeven, Michiel A.,Antonioli, Gian Carlo,Carravetta, Marina,Duma, Luminita,Bovee-Geurts, Petra H. M.,Johannessen, Ole G.,De Groot, Huub J. M.,Lugtenburg, Johan,Emsley, Lyndon,Brown, Steven P.,Brown, Richard C. D.,DeGrip, Willem J.,Levitt, Malcolm H.

, p. 3878 - 3879 (2007/10/03)

A new double-quantum solid-state NMR pulse sequence is presented and used to measure one-bond 13C-13C J-couplings in a set of 13C2-labeled rhodopsin isotopomers. The measured J-couplings reveal a perturbation of the electronic structure at the terminus of the conjugated chain but show no evidence for protein-induced electronic perturbation near the C11-C12 isomerization site. This work establishes NMR methodology for measuring accurate 1JCC values in noncrystalline macromolecules and shows that the measured J-couplings may reveal local electronic perturbations of mechanistic significance. Copyright

Stereocontrolled synthesis of acyclic terpenoids via N-ylide [2,3]rearrangement of ammonium salts with the stereodefined isoprene unit

Honda, Kiyoshi,Tabuchi, Masayuki,Kurokawa, Hiroki,Asami, Masatoshi,Inoue, Seiichi

, p. 1387 - 1396 (2007/10/03)

Stereocontrolled elongation of a functionalized isoprene unit on the E or Z terminal methyl of terpenoids was achieved by N-ylide rearrangement of the common ammonium salts under selected reaction conditions. A 1,5-diene or conjugated triene skeleton can be furnished by reductive or oxidative removal of the amino group of the rearrangement product, respectively. As an application to natural-product synthesis, all-(E)-terpenoid (E)-11d and (E,Z)-terpenoid (Z)-11c were converted into β-sinensal and (13Z)-retinol, respectively. General aspects of these transformations and a plausible transition state for the N-ylide rearrangement are discussed.

A pericyclic cascade to the stereocontrolled synthesis of 9-cis- retinoids

Iglesias, Beatriz,Torrado, Alicia,De Lera, Angel R.,Lopez, Susana

, p. 2696 - 2705 (2007/10/03)

A domino reaction that is pericyclic in nature is thought to be triggered upon treatment of alkenynol 10 with arylsulfenyl chlorides. The process comprises an ordered sequence of sigmatropic rearrangements: a reversible [2,3]-allyl sulfenate to allyl sulfoxide shift, followed by a [2,3]-propargyl sulfenate to allenyl sulfoxide rearrangement, and last a stereodifferentiating [1,5]-sigmatropic hydrogen migration leading to polyene 13. The occurrence of the C7 to C11 hydrogen migration has been demonstrated by labeling experiments. The double diastereoselection of the [1,5]- sigmatropic hydrogen shift to afford a single isomer of the final polyene 13 is thought to arise from a combination of the electronic effect of the sulfoxide at one terminus, and the steric effect imparted by the bulky trimethylcyclohexenyl substituent at the other terminus. The overall process thus constitutes a stereoselective synthesis of an E,Z,Z-triene fragment from an alkenynol and, in particular, a retinoid with the 7E,9Z,11Z,13E configuration on the conjugated polyenic side chain. Application of this method to the synthesis of retinoids, including labeled analogues, is straightforward.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 2052-63-3